Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ning

Showing results (211-220 of 231) with videos related to

Pageof 24
Sort By:
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
Blood Cancer Journal|October 3, 2015
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4C C Bjorklund, L Lu, J Kang, et al.
The Pharmacogenomics Journal|October 28, 2015
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancerY Sunakawa, S Cao, M D Berger, et al.
American Journal of Human Genetics|June 28, 2000
An optimized set of human telomere clones for studying telomere integrity and architectureS J Knight, C M Lese, K S Precht, et al.
British Journal of Cancer|May 24, 2012
Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasisY S Lee, I Choi, Y Ning, et al.
Molecular and Cellular Biology|January 16, 1999
Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genesM J Bertram, N G Bérubé, X Hang-Swanson, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
The Pharmacogenomics Journal|June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancerY Sunakawa, S Cao, N B Volz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsY Sunakawa, S Stintzing, S Cao, et al.
The Pharmacogenomics Journal|April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patientsS Matsusaka, A H Wu, S Cao, et al.
Pageof 24

Showing results (211-220 of 231) with videos related to

Sort By:
Pageof 24
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
Blood Cancer Journal|October 3, 2015
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4C C Bjorklund, L Lu, J Kang, et al.
The Pharmacogenomics Journal|October 28, 2015
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancerY Sunakawa, S Cao, M D Berger, et al.
American Journal of Human Genetics|June 28, 2000
An optimized set of human telomere clones for studying telomere integrity and architectureS J Knight, C M Lese, K S Precht, et al.
British Journal of Cancer|May 24, 2012
Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasisY S Lee, I Choi, Y Ning, et al.
Molecular and Cellular Biology|January 16, 1999
Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genesM J Bertram, N G Bérubé, X Hang-Swanson, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
The Pharmacogenomics Journal|June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancerY Sunakawa, S Cao, N B Volz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsY Sunakawa, S Stintzing, S Cao, et al.
The Pharmacogenomics Journal|April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patientsS Matsusaka, A H Wu, S Cao, et al.
Pageof 24